My Blog
1st case in India on : 30th January, 2020
Today is Day : 509
New Cases Today : 53256
Recovered Cases Today : 78190
Deaths Today : 1422
Total Cases till date : 29935222
Total Active Cases : 702887
Total Recovered Cases : 28844200
Total Deaths : 388135
Active Cases (%) : 2.35%
Recovered Cases (%) : 96.36%
Mortality (%) : 1.30%
Total Vaccinations done since 16th January, 2021 : 28,00,36,898
1st case in India on : 30th January, 2020
Today is Day : 508
New Cases Today : 58419
Recovered Cases Today : 87619
Deaths Today : 1576
Total Cases till date : 29881966
Total Active Cases : 729243
Total Recovered Cases : 28766010
Total Deaths : 386713
Active Cases (%) : 2.44%
Recovered Cases (%) : 96.27%
Mortality (%) : 1.29%
Total Vaccinations done since 16th January, 2021 : 27,66,93,572
A single pill of the investigational drug molnupiravir taken twice a day for 5 days eliminated SARS-CoV-2 from the nasopharynx of 49 participants.
That led Carlos del Rio, MD, distinguished professor of medicine at Emory University in Atlanta, Georgia, to suggest a future in which a drug like molnupiravir could be taken in the first few days of symptoms to prevent severe disease, similar to Tamiflu for influenza.
“I think it’s critically important,” he told Medscape Medical News of the data. Emory University was involved in the trial of molnupiravir but del Rio was not part of that team. “This drug offers the first antiviral oral drug that then could be used in an outpatient setting.”
1st case in India on : 30th January, 2020
Today is Day : 507
New Cases Today : 60753
Recovered Cases Today : 97743
Deaths Today : 1647
Total Cases till date : 29823547
Total Active Cases : 760019
Total Recovered Cases : 28678391
Total Deaths : 385137
Active Cases (%) : 2.55%
Recovered Cases (%) : 96.16%
Mortality (%) : 1.29%
Total Vaccinations done since 16th January, 2021 : 27,23,88,783